| Entry |
|
|---|
| Name |
Dutasteride (JAN/USP/INN);
Avodart (TN) |
|---|
| Product |
|
|---|
| Generic |
DUTASTERIDE (A-S Medication Solutions), DUTASTERIDE (Amneal Pharmaceuticals LLC), DUTASTERIDE (Bryant Ranch Prepack), DUTASTERIDE (Bryant Ranch Prepack), DUTASTERIDE (Bryant Ranch Prepack), DUTASTERIDE (Cadila Healthcare Limited), DUTASTERIDE (Camber Pharmaceuticals), DUTASTERIDE (Epic Pharma), DUTASTERIDE (Golden State Medical Supply), DUTASTERIDE (Humanwell PuraCap Pharmaceutical (Wuhan)), DUTASTERIDE (MARKSANS PHARMA LIMITED), DUTASTERIDE (NuCare Pharmaceuticals), DUTASTERIDE (Proficient Rx LP), DUTASTERIDE (Proficient Rx LP), DUTASTERIDE (PuraCap Pharmaceutical LLC), DUTASTERIDE (REMEDYREPACK), DUTASTERIDE (Strides Pharma Science Limited), DUTASTERIDE (Viona Pharmaceuticals), DUTASTERIDE (XLCare Pharmaceuticals) |
|---|
| Formula |
C27H30F6N2O2
|
|---|
| Exact mass |
528.2211
|
|---|
| Mol weight |
528.5297
|
|---|
| Structure |
|
|---|
| Class |
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG02925 CYP3A5 substrate
|
|---|
| Remark |
| Therapeutic category: | 2499 |
| Product (mixture): | D11389<US> |
|
|---|
| Efficacy |
Prostatic hyperplasia treatment, Antiandrogen, 5alpha-Reductase inhibitor |
|---|
| Comment |
Treatment of benign prostatic hyperplasia
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576], CYP3A5 [HSA: 1577]
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
G GENITO URINARY SYSTEM AND SEX HORMONES
G04 UROLOGICALS
G04C DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
G04CB Testosterone-5-alpha reductase inhibitors
G04CB02 Dutasteride
D03820 Dutasteride (JAN/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Genitourinary Agents
Benign Prostatic Hypertrophy Agents
Dutasteride
D03820 Dutasteride (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
24 Hormones
249 Miscellaneous
2499 Others
D03820 Dutasteride (JAN/USP/INN)
Target-based classification of drugs [BR:br08310]
Enzymes
Oxidoreductases (EC1)
Dehydrogenases
SRD5A1
D03820 Dutasteride (JAN/USP/INN) <JP/US>
SRD5A2
D03820 Dutasteride (JAN/USP/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D03820
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D03820
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D03820
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D03820
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 37
1 C2x C 28.5514 -21.3770
2 C5x C 28.5514 -22.7540
3 N1x N 29.7439 -23.4425
4 C1y C 30.9364 -22.7540
5 C1z C 30.9364 -21.3770
6 C2x C 29.7439 -20.6885
7 C1x C 32.1289 -23.4425
8 C1x C 33.3214 -22.7540
9 C1y C 33.3214 -21.3770
10 C1y C 32.1289 -20.6885
11 C1y C 34.5140 -20.6885
12 C1z C 34.5140 -19.3115
13 C1x C 33.3214 -18.6230
14 C1x C 32.1289 -19.3115
15 C1x C 36.8990 -20.6885
16 C1x C 36.8990 -19.3115
17 C1y C 35.7065 -18.6230
18 C5a C 35.7065 -17.2460
19 N1b N 36.9030 -16.5552
20 O5a O 34.5180 -16.5597
21 C8y C 38.0809 -17.2353
22 C8x C 38.0810 -18.6227
23 C8y C 39.2735 -19.3111
24 C8x C 40.4660 -18.6226
25 C8x C 40.4660 -17.2352
26 C8y C 39.2734 -16.5468
27 C1d C 39.2734 -15.1698
28 X F 40.6504 -15.1698
29 X F 39.2734 -13.7928
30 X F 37.8964 -15.1698
31 C1d C 39.2735 -20.6881
32 X F 37.8964 -20.6881
33 X F 40.6505 -20.6881
34 X F 39.2735 -22.0651
35 O5x O 27.3589 -23.4425
36 C1a C 30.9364 -20.0000
37 C1a C 34.5140 -17.9345
BOND 41
1 1 2 1
2 2 3 1
3 3 4 1
4 4 5 1
5 5 6 1
6 1 6 2
7 4 7 1
8 7 8 1
9 8 9 1
10 9 10 1
11 5 10 1
12 9 11 1
13 11 12 1
14 12 13 1
15 13 14 1
16 10 14 1
17 11 15 1
18 15 16 1
19 16 17 1
20 12 17 1
21 17 18 1 #Up
22 18 19 1
23 18 20 2
24 19 21 1
25 21 22 2
26 22 23 1
27 23 24 2
28 24 25 1
29 25 26 2
30 21 26 1
31 26 27 1
32 27 28 1
33 27 29 1
34 27 30 1
35 23 31 1
36 31 32 1
37 31 33 1
38 31 34 1
39 2 35 2
40 5 36 1 #Up
41 12 37 1 #Up
|
|---|
